Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.8052W HIGH $32.71
Volume
955.12 K
Value Traded
21.53 M
Short % Float
23.63%
-6.97%Week
+6.4%1 Month
+4.01%3 Month
+65.85%6 Month
-46.27%5 Year
-46.27%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
793.17 M
EPS (TTM)
-1.39
P/E Ratio
-
Ent. Value
612.68 M
Total Shares
45.02 M
Float Shares
44.94 M
Insiders
16.70%
Institutions
97.65%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BBNX Catalyst Timeline
Dated clinical, regulatory and corporate events for Beta Bionics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Beta Bionics, Inc.
30Total events
14Upcoming
7Tier-1 (high impact)
2025 to 2028Coverage
Upcoming catalysts 2
Event history 13
▲Partnership / LicenseCorporate
Beta Bionics partners with Senseonics to integrate iLet Bionic Pancreas and mint with Eversense 365 CGM
diabetessource ↗
▼Equity OfferingCorporate
Closing of $172.5 million underwritten public offering of common stock and pre-funded warrants
▼Equity OfferingCorporate
Pricing of $150.0M public offering of common stock and pre-funded warrants
▲Partnership / LicenseCorporate
Senseonics partners with Beta Bionics to integrate Eversense 365 CGM with iLet Bionic Pancreas
diabetessource ↗
▼Legal / SettlementCorporate
Securities class action filed against Beta Bionics covering July 30, 2025 – Feb. 24, 2026 class period
●NDA SubmissionRegulatory Filing
510(k) application submitted to FDA for 3D Intelligence insulin dosing algorithm
diabetessource ↗
▼Safety Signal DisclosediLetSafety
Alleged concealed iLet safety complaints and hypoglycemic events disclosed
▼Warning Letter IssuediLetCMC / Inspection
FDA issued warning letter to Beta Bionics CEO regarding iLet
type 1 diabetessource ↗
▼Quarterly UpdateCorporate
Updated full year 2026 revenue guidance to approximately $121-126 million
▼Form 483 IssuediLetCMC / Inspection
Beta Bionics received FDA Form 483 after iLet manufacturing inspection
type 1 diabetessource ↗
Past FDA Catalysts and PDUFA Decisions
How BBNX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D29 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 71%
Micro Cap(rank 469 of 660)
Percentile Rank
Beta Bionics, Inc. faces pipeline headwinds (29/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| iLet Bionic Pancreas System, Usual Care UnknownNCT06449677 | Cystic Fibrosis-related Diabetes | Phase 3 | ACTIVE NOT_RECRUITING | 150 | May 31, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every BBNX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| iLet® Bionic Pancreas | type 1 diabetes | 2021-12-22 | approximately 440 adults and children 6 years and older with type 1 diabetesRead More | Beta Bionics Announces Data Lock of the Insulin-Only Bionic Pancreas Pivotal Trial and Enrollment into the Screening Protocol of the Bihormonal Bionic Pancreas Pivotal TrialRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hopman MarkOfficer (Chief Commercial Officer) | Sell | -370 56,109 held | $18.96 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BBNX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 2.4 % (-14.3 %) | 68.85 M | 4.39 M | 73.35% ( 1.86 M) |
BBNX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BBNX ranks across every disease it competes in
Competitive Position is a premium feature
See how BBNX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBBNX News
BBNX▼ -5.4%on this news
Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026
Beta Bionics, Inc. will announce its third quarter 2026 financial results on October 27, 2026. The announcement will follow a conference call and webcast at 4:30 PM ET to discuss the company's performance. The webcast will be available on their website for future access.
Read more →BBNXBeta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365
Beta Bionics has announced a partnership with Senseonics to integrate its iLet Bionic Pancreas and mint automated insulin delivery systems with the Eversense 365 continuous glucose monitoring system. The integrated system is expected to launch commercially in the fourth quarter of 2026, offering users a wider range of choices in diabetes management solutions. This collaboration aims to enhance the treatment experience for individuals living with diabetes.
Read more →BBNXBeta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock
Beta Bionics, Inc. has successfully closed a public offering of 7,652,175 shares at $17.25 each, raising $172.5 million. The offering included pre-funded warrants and was fully subscribed by underwriters. The proceeds will be utilized for general corporate purposes, including the commercialization of their iLet Bionic Pancreas and expansion of manufacturing facilities.
Read more →BBNX▲ +15.3%on this newsshared move
Beta Bionics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Beta Bionics, Inc. has announced the pricing of a public offering of 7,652,175 shares of common stock at $17.25 per share, alongside pre-funded warrants for additional shares. The offering is expected to raise approximately $150 million, which will be used for general corporate purposes, including the commercialization of their iLet Bionic Pancreas. The offering is set to close on September 17, 2026, pending customary conditions.
Read more →BBNX▲ +15.3%on this newsshared move
Beta Bionics Announces Proposed Public Offering of $125.0 Million of Common Stock
Beta Bionics, Inc. announced a proposed public offering of $125 million in common stock, with an option for underwriters to purchase an additional $18.75 million. The proceeds will be used for general corporate purposes, including the commercialization of their iLet Bionic Pancreas. The company has filed a registration statement with the SEC, and there are risks regarding the offering's completion and market conditions.
Read more →BBNXBeta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm
Beta Bionics has received FDA clearance for its Mint patch pump, which features a unique reusable and disposable architecture. The company also introduced its 3D Intelligence insulin dosing algorithm, expected to enhance user customization. Full commercialization of Mint is projected for Q1 2027, with significant manufacturing capacity planned. The launch aims to improve access for diabetes patients through pharmacy channels.
Read more →BBNXSenseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
Senseonics has partnered with Beta Bionics to integrate its Eversense 365 Continuous Glucose Monitoring system with the iLet Bionic Pancreas. This collaboration aims to simplify diabetes management by combining year-long glucose monitoring with automated insulin delivery. The integrated system is expected to launch commercially in Q4 2026, enhancing options for diabetes patients.
Read more →BBNX▼ -5.9%on this news
Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
Beta Bionics reported a 38% increase in net sales for Q2 2026, reaching $32 million. The company also improved its gross margin to 59.0% and saw a significant rise in new patient starts. However, it faced a net loss of $23.4 million and an operating loss of $25.6 million. The company updated its full-year guidance, maintaining revenue estimates between $131 million and $136 million.
Read more →BBNX▲ +6.6%on this news
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
Beta Bionics, Inc. announced it will release its second quarter 2026 financial results on July 29, 2026. A conference call and webcast will follow the release to discuss the company's performance. The iLet Bionic Pancreas, an FDA-cleared device, aims to enhance diabetes management for insulin-requiring individuals.
Read more →BBNXBeta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
Beta Bionics has launched a public dashboard providing near real-time real-world data on its iLet Bionic Pancreas. This innovative approach allows healthcare providers and the diabetes community to access comprehensive outcomes without exclusions. The initiative aims to enhance transparency in automated insulin delivery and sets a new standard for data evaluation in the industry.
Read more →BBNX▲ +11.4%on this news
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development
Beta Bionics has updated its timeline for the commercialization of Mint, an advanced insulin pump, expecting to launch by the end of Q2 2027, pending FDA approval. The company is confident in its manufacturing capabilities to meet demand and believes Mint will significantly enhance diabetes management options for users. Further details will be provided once regulatory clearance is obtained.
Read more →BBNXBeta Bionics to Present at the Bank of America Securities Health Care Conference
Beta Bionics, Inc. will present at the Bank of America Securities Health Care Conference on May 12, 2026. The company focuses on advanced diabetes management solutions and is known for its iLet Bionic Pancreas, the first FDA-cleared insulin delivery device. A live audio webcast of the presentation will be accessible on their investor website, providing insights into the company's developments and offerings.
Read more →BBNXBeta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
Beta Bionics, Inc. reported its financial results for Q1 2026, showing a 57% increase in net sales compared to the same quarter last year, reaching $27.6 million. Despite a decline in new patient starts and a loss from operations of $24.3 million, the company raised its full-year guidance for total revenue. The gross margin exhibited significant improvement, rising to 59.5%. Additionally, recent strategic actions include the launch of a new data analytics feature and the initiation of a Phase 2a trial in New Zealand for their bihormonal system.
Read more →BBNX▲ +11.1%on this news· ran to +22% by day 1
Beta Bionics, Inc. Investigated by the Portnoy Law Firm
Beta Bionics, Inc. is under investigation by the Portnoy Law Firm for possible securities fraud, potentially leading to a class action lawsuit for investors. This development comes after a significant drop in the company's stock price, which fell 37.03% following an earnings report indicating a drastic slowdown in new user acquisitions. The report showed a stark contrast in growth from the previous quarter, leading to diminished investor confidence and increased concerns about the company's future performance. The law firm is offering complimentary evaluations to affected investors, highlighting the potential for pursuing claims due to corporate mismanagement.
Read more →BBNXBeta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
Beta Bionics has launched Bionic Insights, a feature within its Bionic Reports that aims to enhance how healthcare providers make treatment decisions for diabetes patients. This innovative tool provides detailed insights into patient data by categorizing it into areas of success and opportunity, allowing clinicians to focus on actionable outcomes. The development is expected to improve patient care and glucose control by enabling more informed, personalized recommendations. Beta Bionics continues its commitment to simplifying diabetes management through advanced technology.
Read more →BBNX▼ -8.4%on this newsshared move
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
Beta Bionics, Inc. will announce its first quarter 2026 financial results on April 21, 2026. The announcement will be followed by a conference call and webcast at 4:30 PM ET to discuss the company's performance. The iLet Bionic Pancreas, an innovative insulin delivery device, continues to enhance diabetes management.
Read more →BBNXBeta Bionics to Present at the TD Cowen 46th Annual Health Care Conference
Beta Bionics, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. The presentation will focus on the company's advanced diabetes management solutions, specifically their FDA-cleared iLet Bionic Pancreas. The event will conclude with a live audio webcast available on the company's website. This highlights Beta Bionics' role as a pioneering leader in insulin delivery technology.
Read more →BBNXBeta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026
Beta Bionics, Inc. reported its financial results for Q4 and full year 2025, showcasing strong performance and introducing guidance for 2026. The company highlighted its leadership in the durable insulin pump market and the successful completion of a Phase 2a trial for its bihormonal program. CEO Sean Saint expressed confidence in the company's growth trajectory and innovative pipeline.
Read more →BBNXBeta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Beta Bionics, Inc. has announced the release date for its fourth quarter and full year 2025 financial results, scheduled for February 17, 2026. The company will host a conference call and webcast to discuss its performance. The iLet Bionic Pancreas, an FDA-cleared device, exemplifies their commitment to improving diabetes management.
Read more →BBNX▼ -37%on this news
Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics
Beta Bionics, Inc. announced its preliminary, unaudited financial results for the fourth quarter of 2025, highlighting key metrics and inviting investors to in-person meetings to discuss the outcomes. The company plans to release complete financial results on February 17, 2026. The iLet Bionic Pancreas continues to be a significant innovation in diabetes management.
Read more →About Beta Bionics, Inc.
Headquarters11 HUGHES, IRVINE, CA, 92618
BIOPHARMAWATCH ELITE PLUS
Trade the next BBNX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime